Comparison of Tc-99m MAG3 and Tc-99m DTPA in Renal Transplant Patients with Impaired Renal Function
| Autor: | Andrew J. Taylor, Dennis Eshima, Jack A. Ziffer |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Graft Rejection Male Nephrology medicine.medical_specialty Tc 99m dtpa Urology Technetium Tc 99m Mertiatide Impaired renal function Internal medicine medicine Humans Radiology Nuclear Medicine and imaging In patient Radionuclide Imaging Uremia Volume of distribution business.industry Organotechnetium Compounds General Medicine Pentetic Acid Kidney Transplantation Normal volunteers Renal transplant Technetium Tc 99m Pentetate Female Kidney Diseases Transplant patient business Oligopeptides |
| Zdroj: | Clinical Nuclear Medicine. 15:371-378 |
| ISSN: | 0363-9762 |
| DOI: | 10.1097/00003072-199006000-00001 |
| Popis: | Tc-99m mercaptoacetyltriglycine (MAG3) is a new Tc-99m renal agent that compares favorably to I-131 Hippuran in animal models, normal volunteers, and patients. Based on the fact that Tc-99m MAG3 has a much more rapid clearance than Tc-99m DTPA and a smaller volume of distribution, it was postulated that the image quality of Tc-99m MAG3 studies should be superior to scans obtained using Tc-99m DTPA, particularly in patients with impaired renal function. To test this hypothesis, Tc-99m DTPA and MAG3 images were obtained in three transplant patients during periods of stable but impaired renal function. In one study, the Tc-99m DTPA study was potentially misleading, whereas the Tc-99m MAG3 examination assessed the clinical situation correctly. In all three cases, the Tc-99m MAG3 images were superior. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|